Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Curcumin Also Inhibits Metastasis from Prostate Cancer

By BiotechDaily International staff writers
Posted on 23 Oct 2012
Researchers have now shown that curcumin, the key medicinal ingredient of turmeric, can also inhibit formation of metastases from prostate cancer, and have identified the main mechanism by which it does so.


Powdered turmeric has long been used in traditional medicine to treat osteoarthritis and other illnesses. Studies have shown that its active ingredient, the polyphenol curcumin, inhibits inflammatory reactions. A research team led by PD Dr. Beatrice Bachmeier of the Ludwig-Maximilians-University Munich (Munich, Germany) has been studying the effectiveness and the mode of action of curmumin in inhibition of cancer metastasis. In a previous study, Dr. Bachmeier and colleagues had demonstrated that the substance reduces statistically significantly the formation of lung metastases in an animal model of advanced breast cancer.


Prostate cancer is often diagnosed only after metastatic tumors have formed in other organs and emerging evidence suggests that chronic inflammation is a major risk factor for the development and metastatic progression of prostate cancer. The new study, published early online October 5, 2012, in the journal Carcinogenesis, was designed to investigate the efficacy of curcumin in preventing prostate cancer metastases and to determine its mechanism of action. The researchers first examined the molecular processes that are abnormally regulated in the carcinoma cells. Prostate and breast cancers are often associated with latent or chronic inflammatory reactions and, in both cases, the tumor cells were found to abnormally produce proinflammatory immunomodulators including the cytokines CXCL1 und CXCL2. They then observed that, among other inhibiting effects, curcumin specifically decreased the expression of these two proteins and other important metastasis-promoting factors. Furthermore, in a mouse model this effect was correlated with a decline in the incidence of metastases.


Since curcumin is well tolerated, it could be suitable for use in reducing metastatic potential by chemoprevention - for prophylactic use (primary prevention) and/or for the suppression of metastases where an established tumor is already present (secondary prevention). “This does not mean that the compound should be seen as a replacement for conventional therapies. However, it could play a positive role in [prevention or treatment]. In this context the fact that the substance is well tolerated is very important,” said Dr. Bachmeier.


A daily intake of up to 8 g of curcumin is regarded as safe, and its anti-inflammatory properties have long been exploited in traditional medicine. For prophylaxis, men with benign hyperplasia of the prostate (BHP) are one possible target group, as are women with a family history of breast cancer. The agent might also be valuable as a supplement to certain cancer therapies. Since curcumin’s beneficial effects must first be examined in controlled clinical tests, Dr. Bachmeier and colleagues are presently planning a clinical trial in patients suffering from therapy-resistant prostate carcinoma.

Related Links:

Ludwig-Maximilians-University Munich




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: (Left) Neurons in brains from people with autism do not undergo normal pruning during childhood and adolescence. The images show representative neurons from unaffected brains (left) and brains from autistic patients (right); the spines on the neurons indicate the location of synapses (Photo courtesy of Guomei Tang, PhD and Mark S. Sonders, PhD, Columbia University Medical Center).

Autistic Youngsters Found to Have Too Many Brain Synapses

Autistic children and adolescents have been shown to have an excess of brain synapses, and this is due to a slowdown in the normal brain “trimming” process during development, according to new findings.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.